Schnieders Capital Management LLC Purchases 342 Shares of Eli Lilly and Company (NYSE:LLY)

Schnieders Capital Management LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 5.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,224 shares of the company’s stock after acquiring an additional 342 shares during the period. Schnieders Capital Management LLC’s holdings in Eli Lilly and Company were worth $3,628,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the company. Lipe & Dalton purchased a new position in shares of Eli Lilly and Company during the fourth quarter valued at approximately $26,000. Thompson Investment Management Inc. bought a new position in shares of Eli Lilly and Company during the 3rd quarter valued at $27,000. Legacy Financial Group LLC purchased a new position in shares of Eli Lilly and Company in the 3rd quarter worth $35,000. Optiver Holding B.V. bought a new stake in shares of Eli Lilly and Company in the third quarter worth $36,000. Finally, Family CFO Inc purchased a new stake in Eli Lilly and Company during the third quarter valued at $40,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

LLY traded up $14.29 during trading on Tuesday, hitting $745.62. 2,041,595 shares of the company traded hands, compared to its average volume of 3,051,032. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The company has a market cap of $708.46 billion, a PE ratio of 128.56, a P/E/G ratio of 1.58 and a beta of 0.34. The stock’s 50-day simple moving average is $763.89 and its two-hundred day simple moving average is $664.05. Eli Lilly and Company has a 1 year low of $370.68 and a 1 year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.09 earnings per share. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on LLY shares. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. JPMorgan Chase & Co. lifted their price target on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research note on Friday, March 15th. Citigroup boosted their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Finally, The Goldman Sachs Group raised their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $728.05.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.